IceCure Medical has issued bonds worth US$5.7 million
IceCure Medical Ltd. has completed a fundraising to refinance and develop the company.
IceCure is an Israeli medical device company that has developed technology to eliminate benign and cancerous tumors in the breast and other parts of the body by freezing the tumor during treatment in a clinic and without surgery, using the ProSense system developed at the Elisha Private Hospital in Haifa.
Oaklins’ team in Israel advised IceCure Medical Ltd. and acted as the leader of the distributors’ consortium.
Talk to the deal team
Related deals
Alcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Learn moreA group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn moreShield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Learn more